Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral vector-based gene therapy ? ET3 ? for hemophilia A at the Annual Meeting of the American ...

SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of ...

Investigators said patients experienced adverse effects in line with those expected for myeloablative conditioning with ...

Innate Pharma antibody pits natural killer cells against ... T cells in the lab for ex vivo CAR-T cell therapies. Vyriad’s lentivirus vectors target T cells within a patient’s body and deliver ...